Welcome to our dedicated page for Evogene SEC filings (Ticker: EVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Evogene’s multi-subsidiary disclosures can feel overwhelming; a single 10-K packs gene-editing breakthroughs, microbiome trial results, and castor-seed revenue into more than 300 pages. That’s why Stock Titan offers Evogene SEC filings explained simply. Whether you need the science behind MicroBoost AI or the cash burn of Biomica, our AI highlights the essentials and drops you at the exact section—no manual scrolling.
Ask natural questions like “Where can I find the Evogene quarterly earnings report 10-Q filing?” or “Track Evogene insider trading Form 4 transactions.” Our platform answers in plain English and links directly to each document. Real-time feeds push Evogene Form 4 insider transactions real-time to your dashboard, while instant cards titled “Evogene 8-K material events explained” flag every development. Built-in analytics surface R&D spend shifts and segment margins, turning raw text into insight faster than you can open EDGAR.
For deeper research, dive into the Evogene annual report 10-K simplified to uncover revenue by tech-engine, or open the Evogene proxy statement executive compensation to review option grants and board pay. AI-curated dashboards show Evogene executive stock transactions Form 4 alongside price performance, giving context to buying or selling. Whether you’re understanding Evogene SEC documents with AI or seeking Evogene earnings report filing analysis for your model, Stock Titan converts complex biotech filings into immediate clarity.
Evogene Ltd. submitted a Form 6-K announcing that it has released its financial results for the third quarter ended September 30, 2025. The company also scheduled a conference call on November 20, 2025 to discuss these quarterly results and made an investor slide presentation available.
The third quarter 2025 financial results are provided in a press release attached as Exhibit 99.1, and the accompanying slide deck is attached as Exhibit 99.2. The GAAP financial statement tables in the press release are incorporated by reference into Evogene’s existing registration statements on Form F-3 and multiple Form S-8 filings, so they now form part of those registration materials from the date of this Form 6-K.
Evogene Ltd. furnished its unaudited condensed consolidated financial statements and an Operating and Financial Review and Prospects for the six-month period ended
FAQ
What is the current stock price of Evogene (EVGN)?
What is the market cap of Evogene (EVGN)?
